GOSS – Gossamer Bio, Inc.
Float Short %
13.04
Margin Of Safety %
Put/Call OI Ratio
0.54
EPS Next Q Diff
EPS Last/This Y
-0.47
EPS This/Next Y
0.12
Price
2.7
Target Price
9.5
Analyst Recom
1.25
Performance Q
22.17
Relative Volume
1.1
Beta
1.94
Ticker: GOSS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | GOSS | 3.23 | 0.30 | 0.18 | 179588 |
| 2025-12-29 | GOSS | 3.21 | 0.30 | 0.14 | 180039 |
| 2025-12-30 | GOSS | 3.13 | 0.30 | 2.98 | 181893 |
| 2025-12-31 | GOSS | 3.11 | 0.32 | 1.59 | 185055 |
| 2026-01-02 | GOSS | 2.84 | 0.32 | 1.34 | 185705 |
| 2026-01-05 | GOSS | 2.73 | 0.34 | 0.78 | 190863 |
| 2026-01-06 | GOSS | 2.56 | 0.36 | 1.89 | 195484 |
| 2026-01-07 | GOSS | 2.4 | 0.35 | 0.17 | 196798 |
| 2026-01-08 | GOSS | 2.5 | 0.30 | 0.50 | 231317 |
| 2026-01-09 | GOSS | 2.51 | 0.29 | 1.84 | 238105 |
| 2026-01-12 | GOSS | 2.52 | 0.35 | 0.41 | 254872 |
| 2026-01-13 | GOSS | 2.65 | 0.35 | 0.05 | 257552 |
| 2026-01-14 | GOSS | 2.54 | 0.34 | 0.50 | 262839 |
| 2026-01-15 | GOSS | 2.44 | 0.34 | 2.03 | 270812 |
| 2026-01-16 | GOSS | 2.53 | 0.34 | 1.19 | 271219 |
| 2026-01-20 | GOSS | 2.6 | 0.48 | 2.68 | 208318 |
| 2026-01-21 | GOSS | 2.74 | 0.53 | 1.11 | 216018 |
| 2026-01-22 | GOSS | 2.86 | 0.54 | 0.74 | 242744 |
| 2026-01-23 | GOSS | 2.7 | 0.54 | 0.77 | 261316 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | GOSS | 3.23 | -27.8 | 125.0 | -0.72 |
| 2025-12-29 | GOSS | 3.21 | -27.8 | 123.7 | -0.72 |
| 2025-12-30 | GOSS | 3.12 | -27.8 | 124.3 | -0.72 |
| 2025-12-31 | GOSS | 3.11 | -27.8 | 123.7 | -0.72 |
| 2026-01-02 | GOSS | 2.88 | -27.8 | 125.3 | -0.72 |
| 2026-01-05 | GOSS | 2.73 | -27.8 | 124.8 | -0.72 |
| 2026-01-06 | GOSS | 2.55 | -27.8 | 125.2 | -0.72 |
| 2026-01-07 | GOSS | 2.40 | -27.8 | 125.0 | -0.72 |
| 2026-01-08 | GOSS | 2.50 | -27.8 | 122.8 | -0.72 |
| 2026-01-09 | GOSS | 2.51 | -27.8 | 123.5 | -0.72 |
| 2026-01-12 | GOSS | 2.52 | -27.8 | 123.5 | -0.72 |
| 2026-01-13 | GOSS | 2.65 | -27.8 | 122.4 | -0.72 |
| 2026-01-14 | GOSS | 2.54 | -27.8 | 124.7 | -0.72 |
| 2026-01-15 | GOSS | 2.44 | -27.8 | 124.6 | -0.72 |
| 2026-01-16 | GOSS | 2.53 | -29.5 | 122.9 | -0.72 |
| 2026-01-20 | GOSS | 2.60 | -29.5 | 122.9 | -0.72 |
| 2026-01-21 | GOSS | 2.74 | -29.5 | 122.3 | -0.72 |
| 2026-01-22 | GOSS | 2.86 | -29.5 | 122.6 | -0.72 |
| 2026-01-23 | GOSS | 2.70 | -29.5 | 124.9 | -0.72 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | GOSS | 0.06 | 2.08 | 10.94 |
| 2025-12-29 | GOSS | 0.06 | 2.08 | 10.94 |
| 2025-12-30 | GOSS | 0.06 | 2.08 | 10.94 |
| 2025-12-31 | GOSS | 0.06 | 2.08 | 10.94 |
| 2026-01-02 | GOSS | 0.06 | 2.08 | 10.94 |
| 2026-01-05 | GOSS | 0.06 | 2.06 | 10.94 |
| 2026-01-06 | GOSS | 0.06 | 2.06 | 10.94 |
| 2026-01-07 | GOSS | 0.06 | 2.06 | 10.94 |
| 2026-01-08 | GOSS | 0.06 | 2.06 | 10.94 |
| 2026-01-09 | GOSS | 0.06 | 2.06 | 10.99 |
| 2026-01-12 | GOSS | 0.06 | 2.09 | 10.99 |
| 2026-01-13 | GOSS | 0.06 | 2.09 | 13.04 |
| 2026-01-14 | GOSS | 0.06 | 2.09 | 13.04 |
| 2026-01-15 | GOSS | 0.06 | 2.09 | 13.04 |
| 2026-01-16 | GOSS | 0.06 | 2.09 | 13.04 |
| 2026-01-20 | GOSS | 0.06 | 2.28 | 13.04 |
| 2026-01-21 | GOSS | 0.06 | 2.28 | 13.04 |
| 2026-01-22 | GOSS | 0.06 | 2.28 | 13.04 |
| 2026-01-23 | GOSS | 0.06 | 2.28 | 13.04 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.21
Avg. EPS Est. Current Quarter
-0.19
Avg. EPS Est. Next Quarter
-0.21
Insider Transactions
0.06
Institutional Transactions
2.28
Beta
1.94
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
8
Growth Score
23
Sentiment Score
94
Actual DrawDown %
82.2
Max Drawdown 5-Year %
-96.8
Target Price
9.5
P/E
Forward P/E
PEG
P/S
14.19
P/B
P/Free Cash Flow
EPS
-0.69
Average EPS Est. Cur. Y
-0.72
EPS Next Y. (Est.)
-0.6
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-354.5
Relative Volume
1.1
Return on Equity vs Sector %
162.4
Return on Equity vs Industry %
178.4
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
124.9
Gossamer Bio, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 144
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today
news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance
stock history GOSS – Gossamer Bio, Inc. invest stock market
stock prices GOSS premarket after hours
ticker GOSS fair value insiders trading